These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16341094)

  • 21. Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.
    Hind D; Wailoo AJ; Sutcliffe P
    Health Expect; 2011 Mar; 14(1):38-47. PubMed ID: 20673243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Funding of patients' groups.
    Slevin M
    Lancet; 2006 Jul; 368(9531):202. PubMed ID: 16844488
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 26. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
    Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
    Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Indications for Herceptin in breast cancer treatment].
    Beuzeboc P
    Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
    Bonneterre ME; Bonneterre J
    Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
    [No Abstract]   [Full Text] [Related]  

  • 31. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 32. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the year. Gutsiness, originality and a willingness to fight for justice were behind many of this year's triumphs in nursing.
    Scott G
    Nurs Stand; 2005 Dec 14-2006 Jan 3; 20(14-16):14-6. PubMed ID: 16372550
    [No Abstract]   [Full Text] [Related]  

  • 34. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
    Láng I; Hitre E
    Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuvant trastuzumab for breast cancer.
    Dent R; Clemons M
    BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471
    [No Abstract]   [Full Text] [Related]  

  • 37. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nursing management considerations with trastuzumab (herceptin).
    Frankel C
    Semin Oncol Nurs; 2000 Nov; 16(4 Suppl 1):23-8. PubMed ID: 11151456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 40. Monoclonal antibody therapies shine in breast cancer clinical trials.
    Hampton T
    JAMA; 2005 Jun; 293(24):2985-9. PubMed ID: 15972551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.